Alkali Metals Limited Overview
Alkali Metals Limited is one of India's oldest specialist producers of sodium-metal derivatives, a niche class of highly reactive reagents (sodium amide, sodium hydride, sodium alkoxides, sodium azide) used to build drug molecules. Founded in 1968 as a state-backed joint venture in Hyderabad, it has evolved into a promoter-controlled, three-plant manufacturer whose portfolio spans sodium derivatives, picoline/pyridine-based heterocycles (amino-, acetyl- and aminomethyl-pyridines), tetrazoles, cyclic compounds, contract "campaign" fine chemicals and a small slate of APIs from a USFDA-inspected unit in Visakhapatnam. Its customers are predominantly pharmaceutical and agrochemical manufacturers in India and overseas, with exports historically 50–62% of sales. The company is sub-scale (FY2026 revenue INR 93.03 Cr), cyclically profitable, working-capital intensive and governed by a founding family that controls 69.59% of equity. Its investment case rests on technical niche depth and export relationships, offset by thin margins, governance friction and succession uncertainty.
What the company does. Alkali Metals manufactures and sells chemicals. Its exchange letterhead describes it as a manufacturer of "Sodium Amide, Sodium Alkoxides, Sodium Hydride, Sodium Azide, Tetrazoles, Amino Pyridines, Pyridine Derivatives, Cyclic Compounds, Fine Chemicals, Intermediates for pharmaceuticals and Active Pharmaceutical Ingredients" (FY2026 results filing, 26 May 2026). ICRA characterises the company as an ISO 9001/14001-certified maker of sodium metal derivatives, picoline-based compounds and cyclic chemicals, supplied primarily to pharmaceutical companies for bulk-drug production (ICRA rationale, Dec 2024).
Company's own segment framing. In its Ind AS 108 segment note the company states that, because it is "predominantly engaged in the manufacture and sale of chemicals where the risks and returns associated with the products are uniform," its only reportable segments are geographic (Domestic and Export), based on customer location (FY2026 audited results, Note 6).
Business model. The company operates a batch, multi-product, made-to-order chemical manufacturing model:
Catalogue reagents: (sodium derivatives) sold repeatedly to bulk-drug makers who use them as bases, reducing agents or azide sources in API synthesis.
Heterocyclic intermediates: (pyridine derivatives, tetrazoles, cyclic compounds) sold as building blocks to pharma and agrochemical customers.
Campaign fine chemicals: higher-margin, customer-specific molecules produced in discrete campaigns, often for export customers. ICRA explicitly attributed FY2024–FY2025 margin pressure partly to "lower sales of high margin campaign products (fine chemical)" (ICRA, Nov 2024).
APIs: from the Visakhapatnam (JNPC) unit, which received USFDA cGMP status in May 2019 (ICRA, Nov 2019).
Revenue model mix. Essentially 100% product sales. There is no disclosed service, subscription or licensing revenue. Contract manufacturing is embedded within product sales (campaign products) and is not separately disclosed.
Value-chain position. Alkali Metals sits in the upstream-to-midstream portion of the pharmaceutical value chain: it buys basic raw materials (sodium metal or precursors, picolines/pyridine bases, solvents, ammonia, hydrogen-handling infrastructure) and converts them into reagents and intermediates sold to API manufacturers. It also participates one step further downstream through its own API slate. It does not sell finished formulations.
Customer types and end-markets.
ICRA (Sep 2021) noted that the top products together contributed roughly two-thirds of sales in FY2020–FY2021 and that one category accounted for 42% of FY2021 sales, indicating meaningful product concentration.
Independent characterisation. Alkali Metals is best understood as a technically differentiated but commercially sub-scale niche reagent house. Handling metallic sodium and its derivatives (pyrophoric hydrides, explosive azides) requires specialised plant, safety systems and permits, which constitutes a genuine barrier to casual entry. However, the company has not converted this niche into scale: revenue has oscillated between INR 55 Cr and INR 98 Cr for a decade, operating margins have rarely exceeded 13.8%, and returns on equity have averaged ~2% over 10 years (Screener.in compilation). Its earnings are highly sensitive to (a) the timing of export campaign orders, (b) inventory build/release (inventory days 223–494 over FY2015–FY2026), and (c) raw-material and power costs. The business behaves like a job-shop with a quality reputation rather than a platform specialty-chemicals franchise.
Strategy
Stated corporate strategy. The company does not publish an investor presentation, investor-day materials or medium-term strategic plan, and holds no earnings calls. Observable strategic themes from filings and AGM proceedings are:
-
Succession and continuity of promoter management — the board twice framed Y.V. Prashanth's elevation as part of the succession plan for the MD (EGM Dec 2022; board May 2026).
-
Working-capital discipline — FY2025 inventory reduction and use of customer advances (ICRA, Jun 2025), carried into FY2026's lower cash conversion cycle (96 days vs. 126).
-
Cost control — FY2026 reductions in manufacturing expenses (−23%), repairs (−10%) and employee cost (−2%).
-
Fine-chemicals / campaign product rebuilding — ICRA links profitability to campaign product volumes; management's specific plans are not publicly disclosed.
-
"Vision 2030" — shareholders asked about the company's 2030 vision and plant visits at the 58th AGM; responses were given by the Company Secretary, but no written targets have been published.
Strategic initiatives in the last 24 months.
Management guidance / medium-term targets: Not publicly disclosed. The company provides no revenue, margin or capex guidance. Third-party projections (e.g., a Tijori Finance scenario table) are not company guidance and are disregarded here.
Products & Services
The company does not disclose product-level revenue, capacity, pricing or launch dates in exchange filings. The catalogue below is assembled from the company's statutory letterhead, ICRA rationales and public company profiles. Pricing is not publicly disclosed for any product (industry practice is negotiated, order-by-order pricing).
Sodium and other metal derivatives (core, legacy franchise)
| Product | Description / function | Typical customer use | Status |
|---|---|---|---|
| Sodium amide (NaNH2) | Strong base; aminating agent | Synthesis of amino-pyridines, indigo-type chemistry, API intermediates | Flagship legacy product; hydrogen by-product recovered at Unit I |
| Sodium hydride (NaH) | Strong non-nucleophilic base; pyrophoric | Deprotonation steps in API synthesis | Active (letterhead) |
| Sodium alkoxides (e.g., sodium methoxide) | Bases / catalysts | Condensation reactions in pharma and agro | Active (letterhead; roic.ai lists sodium methoxide) |
| Sodium azide (NaN3) | Azide source; hazardous | Tetrazole ring formation for "sartan" antihypertensive APIs | Active (letterhead) |
| Potassium and other metal derivatives | Analogous reagents | Specialty synthesis | Listed in catalogue profiles (craft.co) |
Tetrazoles
| Product | Description | Customer use | Status |
|---|---|---|---|
| Tetrazole derivatives | Five-membered nitrogen heterocycles made from azides | Sartan-class APIs (e.g., losartan-type chemistry), specialty materials | Active (letterhead); specific grades not disclosed |
Pyridine / picoline derivatives
| Product family | Named compounds | Customer use | Status |
|---|---|---|---|
| Amino pyridines | Category named on letterhead; specific grades not disclosed | Pharma intermediates | Active |
| Aminomethyl pyridines | 3-(Aminomethyl)pyridine; 4-(Aminomethyl)pyridine | Pharma/agro building blocks | Active (product listing, Wright Research profile) |
| Acetylpyridine compounds | 2-Acetylpyridine; 3-Acetylpyridine; 4-Acetylpyridine; 2-Acetyl-4-methylpyridine; N-(6-methyl-2-pyridyl)acetamide | Pharma/agro intermediates; flavour precursors | Active (product listing) |
| Other pyridine derivatives | 2,5-DB3MP (commercialised 2013) | Agro/pharma intermediate | Active (roic.ai) |
Cyclic compounds and fine chemicals
| Product family | Description | Customer use | Status |
|---|---|---|---|
| Cyclic compounds | Carbocyclic/heterocyclic intermediates | Pharma, agro | Active (letterhead) |
| Fine chemicals ("campaign products") | Customer-specific molecules produced in campaigns, mainly for export | Innovator/CDMO customers | Active; ICRA notes these are higher-margin and lumpy |
| Boronic acids, azaindoles | Cross-coupling and kinase-scaffold building blocks | Medicinal chemistry, scale-up | Listed in catalogue profile (craft.co) |
| DSSC / OLED materials | Electronic materials | Display / solar research | Listed in catalogue profile (craft.co) |
Active Pharmaceutical Ingredients (Visakhapatnam / JNPC unit)
| API | Therapeutic class | Notes |
|---|---|---|
| Benzocaine | Local anaesthetic | Listed API |
| Fluconazole | Antifungal | Listed API |
| Loperamide hydrochloride | Antidiarrhoeal | Listed API |
| Losartan potassium | Antihypertensive (sartan; tetrazole-containing) | Strategic fit with in-house azide/tetrazole chemistry |
| Metformin hydrochloride | Antidiabetic | Highly commoditised, large-volume API |
| Phenylephrine hydrochloride | Decongestant | Listed API |
| Rabeprazole sodium | Proton-pump inhibitor | Listed API; pyridine-containing |
Source: product listing reproduced in Wright Research company profile (Sep 2026). Regulatory filings (DMFs, CEPs) for these APIs are not disclosed in sources reviewed. The USFDA cGMP status of the Visakhapatnam unit dates to May 2019 (ICRA Nov 2019); the date and outcome of any subsequent USFDA inspection is not publicly disclosed.
Services. No separately disclosed services. Custom synthesis/contract manufacturing is bundled within fine-chemical campaign sales.
Financial Narrative
Sources: FY2022–FY2026 annual figures from Screener.in compilation of audited filings (cross-checked to FY2026 and FY2025 audited results filed 26 May 2026 and 19 May 2025). "EBITDA" = revenue less operating expenses before other income (Screener "operating profit"). Operating income (EBIT) = EBITDA − depreciation. All amounts INR Cr unless stated.
Income statement
Gross profit is not consistently disclosed; the company reports cost of materials and changes in inventory but aggregators reclassify lines inconsistently. From the audited statements, material margin (revenue less materials consumed and inventory change) was INR 38.70 Cr (47.0%) in FY2025 and INR 45.96 Cr (49.4%) in FY2026. StockAnalysis (S&P-sourced) reports gross profit of INR 50.76 Cr (FY2022), 49.11 Cr (FY2023), 48.36 Cr (FY2024), 36.62 Cr (FY2025) and 31.30 Cr (FY2026); its FY2026 figure follows a changed cost classification and is not comparable — discrepancy noted.
Margins and growth
Revenue CAGR: FY2021–FY2026 (5-year) 10.9% (from the COVID-depressed INR 55.38 Cr base); FY2022–FY2026 (4-year) 0.6%; 10-year ~2% (Screener). The 5-year figure flatters; on a normalised base the business has been essentially flat in nominal terms since FY2015 (INR 68.44 Cr).
Balance sheet
Note on discrepancy: the audited FY2026 Statement of Assets and Liabilities shows total assets of INR 95.55 Cr (FY2025: INR 92.94 Cr) and total equity of INR 44.69 Cr (FY2025: INR 44.52 Cr). The Screener total-asset series nets certain deferred-tax items; equity agrees.
Detailed balance sheet, last two years (INR Cr; audited, 26 May 2026):
At 30 September 2026, Screener shows borrowings rising to INR 21.05 Cr, other liabilities INR 31.30 Cr and reserves INR 33.42 Cr (after FY2026 dividend payout), consistent with working capital absorption from higher Q2 FY2027 sales.
Cash flow
Capex for FY2022–FY2024 is derived as operating cash flow less Screener free cash flow; FY2025 audited gross purchase of PP&E was INR 1.31 Cr with INR 0.49 Cr asset-sale proceeds. Dividends paid for FY2022–FY2024 are derived from prior-year DPS × 1.018 Cr shares; FY2025 and FY2026 are as reported in audited cash flow statements. FY2026 working capital absorbed INR 4.91 Cr (receivables +INR 4.68 Cr, inventories +INR 2.15 Cr, offset partly by payables) versus a release of INR 8.19 Cr in FY2025.
Ratios
Current ratio (audited balance sheet): 1.01x at 31 Mar 2025 and 1.13x at 31 Mar 2026; earlier years not computed from sources reviewed. Net debt/EBITDA FY2026 ≈ 2.18x (INR 16.86 Cr / INR 7.72 Cr). ROE, ROA, D/E, coverage and turnover are analyst calculations from Screener data; ROCE and working-capital days are Screener-reported.
Commentary on trends, inflections and drivers
FY2022 — cyclical peak. Revenue surged 64% to INR 91.02 Cr as pharma customers restocked post-COVID and export campaign orders recovered. EBITDA margin reached 12.5% and net profit INR 3.48 Cr, the best result in a decade. Operating cash flow of INR 11.19 Cr allowed debt reduction to INR 17.25 Cr.
FY2023–FY2024 — slow erosion. Revenue slipped 3% and 6% respectively; EBITDA margins compressed from 12.5% to 10.0%. ICRA attributed weakness to low capacity utilisation, lower sales of high-margin campaign fine chemicals and elevated inventory (inventory days peaked at 382 in FY2024). Borrowings rose to INR 23.82 Cr in FY2023 to fund working capital. Interest coverage fell to 1.44x in FY2024, below ICRA's stated downgrade sensitivity of 2x.
FY2025 — the trough. Three consecutive operating losses in Q1–Q3 FY2025 (Q1 operating margin −11.8%) took full-year EBITDA negative (−INR 0.63 Cr). An exceptional charge of INR 2.31 Cr (characterised by one aggregator as a doubtful-debt provision) deepened the pre-tax loss to INR 8.04 Cr. A deferred-tax credit cushioned the net loss to INR 5.80 Cr. Management released working capital aggressively — inventories fell INR 7.39 Cr and healthy customer advances arrived in Q4 (ICRA, Jun 2025) — keeping operating cash flow positive at INR 5.25 Cr despite the loss. Other income included a one-off INR 1.03 Cr lease-liability write-back. The dividend was halved to INR 0.50.
FY2026 — recovery on mix and cost. Revenue grew 13% to a record INR 93.03 Cr. EBITDA recovered to INR 7.72 Cr (8.3% margin), aided by: lower manufacturing expenses (INR 4.55 Cr vs. INR 5.93 Cr), flat power cost, lower employee cost and a sharply lower depreciation charge (INR 2.89 Cr vs. INR 4.15 Cr, as FY2025 included INR 0.77 Cr right-of-use amortisation and assets aged). PBT was INR 3.32 Cr, but net profit was only INR 0.56 Cr because the company reversed INR 1.97 Cr of lapsed, unutilised MAT credit plus INR 0.79 Cr deferred tax. Earnings were extremely back-ended: Q4 FY2026 alone delivered PBT of INR 5.30 Cr against a nine-month loss of INR 1.98 Cr. Cash conversion was poor (CFO/EBITDA 37%) because Q4 export sales were largely uncollected at year end.
FY2027 to date. Q1 FY2027 revenue fell 14.8% YoY to INR 17.57 Cr with an EBITDA loss (−INR 0.34 Cr) as materials cost rose to 79% of revenue and power cost jumped 62% YoY. Q2 FY2027 rebounded strongly: revenue +45.2% YoY to INR 27.27 Cr, EBITDA INR 1.29 Cr (4.7% margin), PAT INR 0.58 Cr (EPS INR 0.56). H1 FY2027 revenue was INR 44.83 Cr (+13.8%) with a near-breakeven net loss of INR 0.07 Cr. TTM (to Sep 2026) revenue is INR 98.48 Cr, EBITDA INR 6.77 Cr and PAT INR 2.57 Cr (Screener). Gross margin pressure is visible: H1 FY2027 materials consumed rose to INR 28.40 Cr from INR 20.85 Cr in H1 FY2026 on 13.8% revenue growth, implying adverse raw material pricing or product mix.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Revenue by Segment (%)
| Segment | FY2025 | FY2026 |
|---|---|---|
Domestic revenue (INR Cr) | 31.44 | 47.34 |
Export revenue (INR Cr) | 50.89 | 45.69 |
Total revenue from operations (INR Cr) | 82.33 | 93.03 |
Domestic share of revenue (%) | 38.2 | 50.9 |
Export share of revenue (%) | 61.8 | 49.1 |
Segment | YoY growth FY2026 | Segment operating income |
Domestic | +50.6% | — |
Export | −10.2% | — |
Total | +13.0% | PBT INR 3.32 Cr (company level) |
“—” = not publicly disclosed.
Revenue by Segment
| Segment | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Domestic revenue (INR Cr) | 9.42 | 11.12 | 16.09 | 10.72 | 11.20 |
Export revenue (INR Cr) | 11.19 | 7.66 | 8.82 | 18.01 | 6.37 |
Total revenue (INR Cr) | 20.61 | 18.77 | 24.91 | 28.73 | 17.57 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (Annual)
| Segment | FY2025 | FY2026 |
|---|---|---|
Domestic receivables (INR Cr) | 4.72 | 4.86 |
Export receivables (INR Cr) | 9.61 | 14.55 |
Total receivables (INR Cr) | 14.34 | 19.41 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 91.02 | 88.23 | 82.86 | 82.33 | 93.03 |
Operating expenses (INR Cr) | 79.64 | 78.55 | 74.57 | 82.96 | 85.31 |
EBITDA (INR Cr) | 11.38 | 9.68 | 8.29 | -0.63 | 7.72 |
Depreciation (INR Cr) | 3.86 | 4.29 | 4.60 | 4.15 | 2.89 |
Operating income EBIT (INR Cr) | 7.52 | 5.39 | 3.69 | -4.78 | 4.83 |
Other income incl exceptional (INR Cr) | 0.14 | 1.05 | 0.42 | -0.75 | 0.61 |
Interest (INR Cr) | 2.63 | 2.67 | 2.56 | 2.51 | 2.13 |
Pre-tax income (INR Cr) | 5.03 | 3.77 | 1.55 | -8.04 | 3.31 |
Net income (INR Cr) | 3.48 | 2.91 | 1.13 | -5.80 | 0.56 |
EPS basic and diluted (INR) | 3.42 | 2.86 | 1.11 | -5.70 | 0.55 |
Dividend per share declared for year (INR) | 2.00 | 2.00 | 1.00 | 0.50 | 1.00 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EBITDA margin (%) | 12.50 | 10.97 | 10.00 | -0.77 | 8.30 |
Operating EBIT margin (%) | 8.26 | 6.11 | 4.45 | -5.81 | 5.19 |
Pre-tax margin (%) | 5.53 | 4.27 | 1.87 | -9.77 | 3.56 |
Net margin (%) | 3.82 | 3.30 | 1.36 | -7.04 | 0.60 |
Revenue growth YoY (%) | 64.36 | -3.07 | -6.09 | -0.64 | 13.00 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets per Screener (INR Cr) | 96.75 | 101.92 | 105.51 | 91.08 | 92.87 |
Shareholders equity (INR Cr) | 52.08 | 52.86 | 51.34 | 44.52 | 44.69 |
Total borrowings (INR Cr) | 17.25 | 23.82 | 22.84 | 18.18 | 18.13 |
Net fixed assets (INR Cr) | 46.27 | 49.47 | 47.29 | 41.03 | 38.46 |
Capital work in progress (INR Cr) | 0.63 | 1.33 | 0.19 | 0.00 | 0.00 |
Other liabilities (INR Cr) | 27.42 | 25.24 | 31.33 | 28.38 | 30.05 |
Financial Analysis
| Line item | 31 Mar 2025 | 31 Mar 2026 |
|---|---|---|
Property, plant & equipment | 41.03 | 38.46 |
Deferred tax asset (MAT credit) | 5.23 | 3.26 |
Inventories | 26.69 | 28.84 |
Trade receivables | 14.34 | 19.41 |
Cash & cash equivalents | 0.04 | 0.05 |
Other bank balances | 0.57 | 0.94 |
Total current assets | 46.00 | 53.20 |
Non-current borrowings | 0.23 | 0.00 |
Current borrowings (working capital) | 17.69 | 17.85 |
Total borrowings (filing basis) | 17.92 | 17.85 |
Net debt (borrowings less cash and bank balances) | 17.31 | 16.86 |
Trade payables | 19.25 | 26.27 |
Other current liabilities (incl. customer advances) | 7.39 | 2.17 |
Total current liabilities | 45.34 | 46.98 |
Working capital (current assets less current liabilities) | 0.66 | 6.22 |
Total equity | 44.52 | 44.69 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Cr) | 11.19 | 11.19 | 6.29 | 5.25 | 2.82 |
Capital expenditure (INR Cr) | 2.86 | 3.14 | 1.69 | 0.82 | 0.32 |
Free cash flow (INR Cr) | 8.33 | 8.05 | 4.60 | 4.43 | 2.50 |
Dividends paid (INR Cr) | 0.81 | 2.04 | 2.04 | 1.02 | 0.51 |
Share buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%) | 6.9 | 5.5 | 2.2 | -12.1 | 1.3 |
ROA on average assets (%) | 3.6 | 2.9 | 1.1 | -5.9 | 0.6 |
ROCE as ROIC proxy (%) | 11.11 | 8.94 | 5.99 | -4.70 | 8.67 |
Debt to equity (x) | 0.33 | 0.45 | 0.44 | 0.41 | 0.41 |
Total debt to EBITDA (x) | 1.52 | 2.46 | 2.76 | -28.86 | 2.35 |
Interest coverage EBIT to interest (x) | 2.86 | 2.02 | 1.44 | -1.90 | 2.27 |
Asset turnover (x) | 0.94 | 0.89 | 0.80 | 0.84 | 1.01 |
Debtor days | 53.74 | 56.63 | 79.16 | 63.57 | 76.15 |
Inventory days | 245.90 | 277.93 | 381.69 | 223.28 | 223.59 |
Payable days | 165.04 | 180.30 | 281.00 | 161.04 | 203.67 |
Cash conversion cycle (days) | 134.59 | 154.26 | 179.84 | 125.82 | 96.08 |
Revenue by Region
| Region | FY2025 | FY2026 |
|---|---|---|
Domestic India (INR Cr) | 31.44 | 47.34 |
Export rest of world (INR Cr) | 50.89 | 45.69 |
Revenue by Region (H1FY25–H1FY26)
| Region | H1FY25 | H1FY26 |
|---|---|---|
Domestic India (INR Cr) | 14.65 | 20.53 |
Export rest of world (INR Cr) | 20.47 | 18.85 |
Geographic Revenue
| Region | FY2026 YoY | H1 FY2026 YoY | Q1 FY2027 YoY |
|---|---|---|---|
Domestic | +50.6% | +40.1% | +18.9% |
Export | −10.2% | −7.9% | −43.1% |
Valuation Snapshot
| Metric | Value |
|---|---|
Share price | INR 86.6 |
Market capitalisation | ~INR 88.1 Cr |
52-week high / low | INR 106 / INR 46.8 |
Book value per share | INR 42.8 |
TTM EPS (to Sep 2026) | INR 2.52 |
Dividend yield | 1.16% |
Shares outstanding | 1,01,82,506 |
Free float | 30.41% |
Share Price & Returns
| Horizon | Return |
|---|---|
1 year | −2% |
3 years (CAGR) | −9% |
5 years (CAGR) | 0% |
10 years (CAGR) | −1% |
Valuation Multiples
| Multiple | Alkali Metals | Basis |
|---|---|---|
P/E (TTM) | 34.3x | Screener |
P/B | 2.0x | INR 86.6 / INR 42.8 |
EV | ~INR 108 Cr | Market cap INR 88.1 Cr + borrowings INR 21.05 Cr (Sep 2026) − cash ~INR 1 Cr |
EV/Sales (TTM) | ~1.10x | TTM revenue INR 98.48 Cr |
EV/EBITDA (TTM) | ~16.0x | TTM EBITDA INR 6.77 Cr |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Dividend per share (INR) | 0.80 | 2.00 | 2.00 | 1.00 | 0.50 | 1.00 |
Dividend payout ratio (%) | -67.31 | 58.51 | 69.97 | 90.09 | -8.78 | 181.79 |
Credit Ratings
| Agency | Facility | Rating | Outlook | Date |
|---|---|---|---|---|
ICRA | Long-term fund-based (INR 18 Cr) | [ICRA]BB+ | Stable (revised from Negative) | 3–6 Jul 2026 |
ICRA | Short-term non-fund-based (INR 7 Cr) | [ICRA]A4+ | — | 3–6 Jul 2026 |
Moody's / S&P / Fitch | — | Not rated | — | — |
Bucket Details
| Bucket | 31 Mar 2026 (INR Cr) |
|---|---|
Current borrowings (≤12 months; working-capital lines) | 17.85 |
Non-current borrowings | 0.00 |
Total | 17.85 |
Analyst Conclusions
Management guidance: None published. Consensus expectations: None (no analyst coverage).
Analyst baseline view (not guidance). H1 FY2027 delivered revenue of INR 44.83 Cr (+13.8%) at near breakeven. If H2 FY2027 follows seasonal patterns (H2 FY2026 revenue INR 53.64 Cr, with a strong Q4), FY2027 revenue in the region of INR 95–105 Cr is plausible, but the margin outcome hinges on raw-material and power costs and on Q4 export campaigns. With the MAT-credit reversal largely behind (deferred tax asset reduced to INR 3.26 Cr), reported tax drag should be smaller than in FY2026.
Bull case
-
Operating leverage on spare capacity: Q4 FY2026 showed a 21% EBITDA margin at INR 28.7 Cr quarterly revenue; Q2 FY2027 delivered INR 27.3 Cr. Sustaining ~INR 27–29 Cr quarterly revenue without capex could lift annual EBITDA well above the FY2022 peak of INR 11.4 Cr.
-
Domestic substitution momentum: Domestic revenue grew 50.6% in FY2026 and 18.9% in Q1 FY2027, diversifying away from volatile export campaigns.
-
Credit and governance repair: ICRA's Stable outlook, an unmodified audit under a new auditor, and a potential EGM approval for the ED could narrow the governance discount.
Bear case
-
Earnings quality and fragility: FY2026 profit came entirely from Q4; Q1 FY2027 relapsed to a loss; 10-year ROE ~2%. At 34x TTM earnings and ~16x EV/EBITDA, the stock prices in a durable recovery the record does not support.
-
Working-capital and credit risk: Export receivables spiked to INR 14.55 Cr at Mar 2026 and borrowings rose to INR 21.05 Cr by Sep 2026; a repeat of FY2025's INR 2.31 Cr exceptional charge would erase a year's profit.
-
Governance overhang: Public shareholders blocked the MD's reappointment and the ED's appointment; the MD (74) faces term expiry on 30 Apr 2027; 30% of promoter shares are pledged; no institutional holders.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Q4 CY2026 | EGM to approve Y.V. Prashanth as ED — outcome and voting pattern |
| By Apr 2027 | Resolution of MD succession before 30 Apr 2027 term expiry |
| Mid-Jan / Feb 2027 | Q3 FY2027 results — margin sustainability, export recovery |
| May 2027 | FY2027 audited results — receivable provisions, cash conversion, dividend |
| Ongoing | Export receivable collection vs. Mar 2026 peak (INR 14.55 Cr) |
| Ongoing | Power & fuel and raw-material cost trajectory amid 11.4% WPI inflation |
| Mid-2027 | ICRA annual surveillance — interest coverage vs. 2x trigger |
| Ongoing | Any USFDA inspection outcome at Visakhapatnam |
| Ongoing | Promoter pledge changes |
Concluding analyst verdict
Alkali Metals is a genuine specialist trapped in a sub-scale, cyclical business model. Its five-decade franchise in sodium-metal derivatives, heterocyclic intermediates and a USFDA-inspected API plant constitutes real, hard-to-replicate technical capability, and the FY2026 recovery — record revenue of INR 93.03 Cr, EBITDA back to INR 7.72 Cr, and a Q4 that printed a 21% margin — demonstrates what the asset base can earn when campaign orders and plant loading align. Q2 FY2027's 45% revenue growth and return to profit reinforce that the FY2025 trough was cyclical rather than terminal.
Yet the long-run evidence is unflattering. Revenue has barely moved in nominal terms since FY2015, ten-year ROE averages about 2%, cash conversion is erratic, and inventory days of 220–380 tie up most of the balance sheet. Profitability remains hostage to a handful of export campaigns and to input costs that are now rising sharply. Reported earnings are further muddied by MAT-credit reversals and exceptional items, making TTM EPS of INR 2.52 a fragile anchor for a 34x multiple.
Governance is the swing factor. The August 2026 rejection of both the managing director's reappointment and his son's executive appointment — however small the voting public — creates a hard deadline: the MD's term ends 30 April 2027. A clean EGM outcome and an articulated succession and growth plan would materially de-risk the story; a prolonged impasse would compound an already illiquid, uncovered, pledge-encumbered stock.
On balance, the dossier supports a cautious/neutral stance: the operating trough appears to have passed and credit risk has eased (ICRA Stable), but valuation now discounts sustained mid-cycle margins that the company has rarely held for more than a few quarters. Evidence of two to three consecutive quarters of 8%+ EBITDA margins with positive operating cash flow, together with resolved leadership, would be required to move to a constructive view.
Prepared from public filings and data sources available as of 19 October 2026.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Age |
|---|---|---|---|---|
Y.S.R. Venkata Rao (Yerramilli Sri Rama Venkata Rao), DIN 00345524 | Managing Director; promoter (67.81% holding) | MD since 1 May 2004 (22+ years); briefly Compliance Officer Jan–May 2017 | Long-serving promoter-manager | 74 (Simply Wall St) |
Y.V. Prashanth, DIN 00345418 | Executive Director (re-appointed by board 12 Oct 2026, subject to EGM); previously ED Nov 2022–Nov 2025; Non-Executive Director Nov 2025–Oct 2026 | Board member since Nov 2022 (earlier stint as ED before that) | B.Pharm (Andhra University); MS Pharmacy (USA); experience in liquidity management, client development, marketing, receivables/payables management; son of the MD | — |
Gayathri Kesavarapu | Chief Financial Officer | In role by May 2026 (start date not disclosed); predecessor K. Uma Kumari per database records | — | — |
Siddharth Dubey | Company Secretary & Compliance Officer | In role since at least May 2025 | — | — |
V.V. Viswanadha Sarma | General Manager – Production | — | Per craft.co | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Category | Notes |
|---|---|---|---|
Dr. J.S. Yadav | Chairman | Independent | — |
Y.S.R. Venkata Rao | Managing Director | Executive, promoter | Current term ends 30 Apr 2027; reappointment rejected by shareholders 21 Aug 2026 |
Y.V. Prashanth | Executive Director (from 12 Oct 2026, subject to EGM) | Executive, promoter group | AGM special resolution failed 21 Aug 2026 |
Mrs. Y. Lalithya Poorna | Director | Non-executive, promoter group (1.08% holder, foreign promoter category) | Re-appointed on rotation Aug 2026; on board since at least 2012 |
Dr. A.R. Prasad | Director | Non-executive, non-independent | Appointed additional director Feb 2021 |
K.V. Suryaprakash Rao (Kotamarthy Venkata Suryaprakash Rao) | Director | Independent | — |
G. Jayaraman | Director | Independent | On board since at least 2012 (long tenure) |
Murali Krishna Chevuturi | Director | Independent | — |
T.V. Rao (Thallapaka V. Rao) | Director | Independent | — |
Sivarama Prasad Bhamidi, DIN 07620679 | Director | Independent | Appointed 20 Jul 2026 for five years (to 19 Jul 2031); background in defence and insolvency per news coverage |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
18 Jul 2025 | Statutory auditor resigned; J V S L & Associates appointed | Company stated outgoing auditor raised no concerns |
10 Nov 2025 | Y.V. Prashanth's ED tenure completed; continued as non-executive | Three-year term from Nov 2022 lapsed |
26 May 2026 | Board proposes Prashanth as ED (from 1 Jun 2026) and MD reappointment (from 1 May 2027) | Described as succession planning |
9–10 Jun 2026 | Independent director resigns (health) | Committees reconstituted |
20 Jul 2026 | S.P. Bhamidi appointed independent director | Approved at AGM |
21 Aug 2026 | Shareholders reject MD reappointment (63.26% for vs. 36.74% against among public votes) and Prashanth's ED appointment (70.93% for vs. 29.07% against); promoters abstained | Special resolutions need 75%; MD aged over 70 requires special resolution |
12 Oct 2026 | Board re-appoints Prashanth as ED for 3 years from 12 Oct 2026, subject to EGM | EGM date not yet announced in sources reviewed |
Major Shareholders
| Holder | Shares | % of equity | Notes |
|---|---|---|---|
Yerramilli Sri Rama Venkata Rao | 69,04,715 | 67.81 | MD / promoter |
Yerramilli Lalithya Poorna | 1,10,000 | 1.08 | Promoter group (foreign) |
Nagalakshmi Kumari Yerramilli | 41,500 | 0.41 | Promoter group |
Krishnaveni Yerramilli | 28,994 | 0.28 | Promoter group |
CDC Industrial Infras Limited | 633 | 0.01 | Promoter group |
Total promoter & promoter group | 70,85,842 | 69.59 | 21,30,000 shares pledged = 30.06% of promoter holding / 20.92% of total equity (Dec 2025) |
Public (≈12,780 shareholders, Jun 2026) | 30,96,664 | 30.41 | Predominantly resident individuals |
FIIs / FPIs | 0 | 0.00 | Exited by Dec 2024 (was 0.55% Mar 2022) |
Mutual funds | 0 | 0.00 | — |
Other DIIs / insurers | 0 | 0.00 | — |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Relative positioning vs. Alkali Metals |
|---|---|---|---|
Pyridine & picoline derivatives | Jubilant Ingrevia Ltd (India) | Listed, integrated | Global-scale pyridine producer; described by broker research as the only scaled non-Chinese pyridine producer; FY2026 revenue ~INR 4,388 Cr — roughly 47x Alkali Metals |
Pyridine & picoline derivatives | Vertellus (USA, private) | Integrated pyridine producer | Major Western supplier; financials not public |
Pyridine & picoline derivatives | Nanjing Red Sun (China) | Integrated pyridine producer | Large Chinese supplier; low-cost |
Sodium alkoxides | Evonik Industries (Germany) | Global chemical major | Leading alkoxide producer; scale and integration far larger |
Sodium alkoxides | BASF (Germany) | Global chemical major | Sodium methylate producer; scale |
Sodium hydride / reactive metal reagents | Chinese and Indian reagent makers (fragmented, many unlisted) | Mixed | Price competition in commodity grades |
Sodium azide / tetrazoles | Chinese and Indian azide producers (unlisted) | Mixed | Sartan supply chain; regulatory sensitivity |
APIs — metformin | Granules India, Aarti Drugs (India) | Listed API majors | Massive scale in metformin; Alkali Metals is marginal |
APIs — losartan / sartans | IPCA Laboratories, Zydus (India) and Chinese makers | Listed / integrated | Integrated sartan chains; Alkali Metals small |
Custom synthesis / fine chemicals | Indian CDMOs (e.g., Jubilant Ingrevia CDMO, numerous unlisted Hyderabad custom-synthesis houses) | Mixed | Competes on niche chemistry and flexibility |
Peer Comparison FY2026
| Metric | Alkali Metals | Jubilant Ingrevia |
|---|---|---|
Revenue | INR 93.03 Cr | ~INR 4,388 Cr (consolidated) |
Revenue growth | +13.0% | +5% |
EBITDA margin | 8.3% | ~13–14% (EBITDA INR 567–607 Cr; sources differ) |
R&D intensity | 1.34% | — |
Net debt / EBITDA | ~2.2x | ~0.99x |



